Embeda, Oxycontin Might Get Abuse-Deterrent Claims With Post-Marketing Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory panel will consider design of epidemiological or observational studies to determine if drugs' abuse-deterrent properties are effective.